Kinarus-Logo_RGB.jpg
Kinarus Therapeutics Reports Preclinical Data in Lung Fibrosis and Discloses Clinical Development Plan
17 janv. 2023 01h00 HE | Kinarus Therapeutic Holding AG
 KIN001 reduced fibrotic damage of the lung in a preclinical fibrosis modelPotential as an effective oral therapy for Idiopathic Pulmonary Fibrosis (IPF)Phase 2 clinical trial in IPF patients in...
Insilico Medicine announces positive topline results of the New Zealand Phase 1 trial of INS018_055, an AI-designed drug for an AI-discovered target
10 janv. 2023 09h00 HE | InSilico Medicine
New York, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Insilico Medicine (“Insilico”), a clinical stage artificial intelligence (AI)-driven drug R&D company, today announces positive topline results of...
Kinarus-Logo_RGB.jpg
Kinarus Therapeutics’ KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5
06 déc. 2022 01h00 HE | Kinarus Therapeutic Holding AG
Kinarus Therapeutics’ KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5 Researchers at Friedrich-Alexander-Universität Erlangen-Nürnberg and Kinarus report...
Algernon Logo 1.png
Algernon Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis
05 déc. 2022 07h00 HE | Algernon Pharmaceuticals
VANCOUVER, British Columbia, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage...
Kinarus-Logo_RGB.jpg
Kinarus Receives USPTO Notice of Allowance for Lead Therapeutic Candidate KIN001
22 nov. 2022 01h00 HE | Kinarus Therapeutic Holding AG
Method-of-use-patent covers KIN001 in ophthalmic diseasesFurther strengthens already granted KIN001 US composition of matter patent Basel, Switzerland, 22 November 2022. Kinarus Therapeutics...
Kinarus-Logo_RGB.jpg
Kinarus Therapeutics Engages Great Health Companion Group to Explore Partnerships in China
16 nov. 2022 01h00 HE | Kinarus Therapeutic Holding AG
Kinarus to explore partnerships in China to fund Phase 2 clinical trials of KIN001 and explore further business opportunitiesMultiple opportunities for KIN001 in indications with high unmet need are...
Kinarus-Logo_RGB.jpg
Kinarus Therapeutics Provides Strategic Update
04 nov. 2022 02h00 HE | Kinarus Therapeutic Holding AG
Exploring financial and strategic options to fund Phase 2 trials of KIN001 in wet age-related macular degeneration and idiopathic pulmonary fibrosisKINFAST phase 2 clinical trial of KIN001 in mild to...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen to Participate at Stifel 2022 Healthcare Conference
01 nov. 2022 07h00 HE | FibroGen, Inc.
SAN FRANCISCO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Stifel 2022...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen to Report Third Quarter 2022 Financial Results
24 oct. 2022 07h00 HE | FibroGen, Inc.
SAN FRANCISCO, Oct. 24, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2022 financial results on Monday, November 7 after the market close. FibroGen will also...
APIE-logo.png
APIE Therapeutics Provides Evidence that Activating the Apelinergic System can Repair and Regenerate Lung Tissue Damaged by Pulmonary Fibrosis
30 août 2022 08h00 HE | APIE Therapeutics
CARY, NC , Aug. 30, 2022 (GLOBE NEWSWIRE) -- APIE Therapeutics (APIE Tx), a preclinical pharmaceutical company pioneering novel and proprietary drugs to activate the apelin receptor (APJ), presented...